SecurityAZN / AstraZeneca Plc
InstitutionGlobal Retirement Partners, Llc
Shares1,851
Value $ 73,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Global Retirement Partners, Llc reports 28.56% decrease in ownership of AZN / AstraZeneca Plc

October 17, 2018 - Global Retirement Partners, Llc has filed a 13F-HR form disclosing ownership of 1,851 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $73,000 USD as of September 30, 2018. Global Retirement Partners, Llc had filed a previous 13F-HR on August 13, 2018 disclosing 2,591 shares of AstraZeneca Plc at a value of $91,000 USD. This represents a change in shares of -28.56 percent and a change in value of -19.78 percent during the quarter.

Other investors with positions similar to Global Retirement Partners, Llc include CENTRAL TRUST Co, First Financial Corp /in/, Vantage Investment Advisors, LLC, Omnia Family Wealth, LLC, KBC Group NV, and Tompkins Financial Corp.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 37.28 1,851 -28.56 73 -19.78 -28 10 10.54
2018-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 35.27 2,591 267.00 91 264.00 66 -0 -1.91
2018-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.68 706 8.95 25 13.64 2 1 4.49
2017-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 33.95 648 0.00 22 0.00 0 0 0.00
2017-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.11 648 30.65 22 29.41 5 -0 -1.09
2017-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 32.34 496 -11.27 17 0.00 -2 2 11.99
2017-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 28.72 559 115.83 17 142.86 9 1 19.77
2016-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 259 7 7 0 0.00

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

Healthcare 16-24% Target Net Gains Pace WallStars For October

2018-10-15 seekingalpha
Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides. (34-0)

3 Large-Cap Pharma Stocks Performing Better Than Industry

2018-10-12 zacks
The Zacks Large-Cap Pharma industry, a 14 medical stock group, has gained 5.4% in the year so far. This industry also features among the top 9% of the 256 Zacks-ranked industries. (9-0)

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

2018-10-12 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major cardiovascular (“CV”) events including CV death, myocardial infarction (“MI”) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). (16-0)

PhaseBio IPO: Data To Be Released In 2018 And 2020

2018-10-12 seekingalpha
PhaseBio is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. With a specialization on the cardiopulmonary space, the company has two product candidates, PB2452 and PB1046. (3-0)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)



CUSIP: 046353108